Natural carriers for application in tuberculosis treatment

References

• Ahmad Z, Maqbool M, Raja A. Nanomedicine for tuberculosis: Insights from animal models. Int J Nano Dimens 2011; 2: 67–84
   Google Scholar
• Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: Formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci 2006a; 48: 171–6
   PubMedGoogle Scholar
• Ahmad Z, Pandey R, Sharma S, Khuller GK. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 2006b; 261: 181–6
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Pandey R, Sharma S, Khuller GK. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents 2006c; 27: 409–16
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 2005a; 251: 19–22
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005b; 26: 298–303
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett 2006d; 258: 200–3
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomed Nanotechnol Biol Med 2007; 3: 239–43
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suárez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release 2002; 79: 29–40
   PubMed Web of Science ®Google Scholar
• Ain Q, Sharma S, Khuller GK, Garg S. Alginate-based oral drug delivery system for tuberculosis: Pharmacokinetics and therapeutic effects. J Antimicrob Chemother 2003; 51: 931–8
   PubMed Web of Science ®Google Scholar
• Al-Qadi S, Grenha A, Carrión-Recio D, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded formulations. J Control Release 2012; 157: 383–90
   PubMed Web of Science ®Google Scholar
• Al-Qadi S, Grenha A, Remuñán-López C. Microspheres loaded with polysaccharide nanoparticles for pulmonary delivery: Preparation, structure and surface analysis. Carbohydr Polym 2011; 86: 25–34
   Web of Science ®Google Scholar
• Anwunobi A, Emeje M. Recent applications of natural polymers in nanodrug delivery. J Nanomed Nanotechnol 2011; S4: 2–7
   Google Scholar
• Armstead A, Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomed 2011; 6: 3281–93
   PubMed Web of Science ®Google Scholar
• Attama A. SLN, NLC, LDC: State of the art in drug and active delivery. Recent Patents Drug Deliv Formulation 2011; 5: 178–87
   PubMedGoogle Scholar
• Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008; 60: 863–75
   PubMed Web of Science ®Google Scholar
• Barrow W. Microsphere technology for chemotherapy of mycobacterial infections. Curr Pharm Des 2004; 10: 3275–84
   PubMed Web of Science ®Google Scholar
• Beneke C, Viljoen A, Hamman J. Polymeric plant-derived excipients in drug delivery. Molecules 2009; 14: 2602–20
   PubMed Web of Science ®Google Scholar
• Blasi P, Schoubben A, Giovagnoli S, Rossi C, Ricci M. Fighting tuberculosis: Old drugs, new formulations. Expert Opin Drug Deliv 2009; 6: 977–93
   PubMed Web of Science ®Google Scholar
• Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, de Sousa A, Borchard G, Junginger HE. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release 2006; 114: 348–58
   PubMed Web of Science ®Google Scholar
• Braz L, Dionísio M, Grenha A. Chitosan-based nanocarriers: Effective vehicles for mucosal protein delivery. Chitosan manufacture, properties and usage, S Davis. Nova Science Publishers, New York 2011; 365–412
   Google Scholar
• Cai Z, Wang Y, Zhu L-J, Liu Z-Q. Nanocarriers: A general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 2010; 11: 197–207
   PubMed Web of Science ®Google Scholar
• Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003; 92: 1085–94
   PubMed Web of Science ®Google Scholar
• Chiellini F, Piras AM, Errico C, Chiellini E. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine 2008; 3: 367–93
   PubMed Web of Science ®Google Scholar
• Devi N, Maji T. Preparation and evaluation of gelatin/sodium carboxymethyl cellulose polyelectrolyte complex microparticles for controlled delivery of isoniazid. AAPS PharmSciTech 2009; 10: 1412–9
   PubMed Web of Science ®Google Scholar
• Doherty T, Andersen P. Vaccines for tuberculosis: Novel concepts and recent progress. Clin Microbiol Rev 2005; 18: 687–702
   PubMed Web of Science ®Google Scholar
• du Toit L, Pillay V, Danckwerts M. Tuberculosis chemotherapy: Current drug delivery approaches. Respir Res 2006; 7: 118–35
   PubMed Web of Science ®Google Scholar
• Dyala’A GG, Malinconico M, Laurienzo P. Marine derived polysaccharides for biomedical applications: Chemical modification approaches. Molecules 2008; 13: 2069–106
   PubMed Web of Science ®Google Scholar
• Florence A. The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual. Pharm Res 1997; 14: 259–66
   PubMed Web of Science ®Google Scholar
• Fonte P, Andrade F, Araújo F, Andrade C, Neves J, Sarmento B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol 2012; 508: 295–314
   PubMed Web of Science ®Google Scholar
• Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv 2010; 23: 207–17
   PubMed Web of Science ®Google Scholar
• George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan — a review. J Control Release 2006; 114: 1–14
   PubMed Web of Science ®Google Scholar
• Grabovac V, Guggi D, Bernkop-Schnurch A. Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev 2005; 57: 1713–23
   PubMed Web of Science ®Google Scholar
• Grenha A, Remuñán-López C, Carvalho ELS, Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm 2008; 69: 83–93
   PubMed Web of Science ®Google Scholar
• Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005; 25: 427–37
   PubMed Web of Science ®Google Scholar
• Hans M, Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002; 6: 319–27
   Web of Science ®Google Scholar
• Hirota K, Tomoda K, Inagawa H, Kohchi C, Soma G-I, Makino K, Terada H. Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria. Pharm Res 2008; 25: 1420–30
   PubMed Web of Science ®Google Scholar
• Hunter RL. On the pathogenesis of post primary tuberculosis: The role of bronchial obstruction in the pathogenesis of cavities. Tuberculosis 2011; 91(Suppl. 1): S6–10
   Web of Science ®Google Scholar
• Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release 2008; 129: 100–6
   PubMed Web of Science ®Google Scholar
• Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992; 78: 43–8
   Web of Science ®Google Scholar
• Lewis C, Mcgee JD. The macrophage. IRL Press, Oxford 1992
   Google Scholar
• Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008; 60: 1650–62
   PubMed Web of Science ®Google Scholar
• Lu E, Franzblau S, Onyuksel H, Popescu C. Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul 2009; 26: 346–54
   PubMed Web of Science ®Google Scholar
• Malafaya P, Silva G, Reis R. Natural–origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering application. Adv Drug Deliv Rev 2007; 59: 207–33
   PubMed Web of Science ®Google Scholar
• Martins S, Sarmento B, Ferreira D, Souto E. Lipid-based colloidal carriers for peptide and protein delivery – Liposomes versus lipid nanoparticles. Int J Nanomed 2007; 2: 595–607
   PubMed Web of Science ®Google Scholar
• Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011; 91: 71–81
   PubMed Web of Science ®Google Scholar
• Mitchison DA, Fourie PB. The near future: Improving the activity of rifamycins and pyrazinamide. Tuberculosis 2010; 90: 177–81
   PubMed Web of Science ®Google Scholar
• Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microspheres. AAPS PharmSciTech 2008; 9: 755–61
   PubMed Web of Science ®Google Scholar
• Mizrahy S, Peer D. Polysaccharides as building blocks for nanotherapeutics. Chem Soc Rev 2012; 41: 2623–40
   PubMed Web of Science ®Google Scholar
• Mosser D. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209–12
   PubMed Web of Science ®Google Scholar
• Murata Y, Jinno D, Liu D, Isobe T, Kofuji K, Kawashima S. The drug release profile from calcium-induced alginate gel beads coated with an alginate hydrolysate. Molecules 2007; 12: 2559–66
   PubMed Web of Science ®Google Scholar
• Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target 2009; 17: 777–87
   PubMed Web of Science ®Google Scholar
• Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: Facts, flaws, and future. Nanomed Nanotechnol Biol Med 2011; 7: 259–72
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother 2004; 53: 635–40
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother 2005a; 55: 430–5
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005b; 85: 227–34
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 2005; 85: 415–20
   PubMed Web of Science ®Google Scholar
• Pinheiro M, Lúcio M, Lima J, Reis S. Liposomes as drug delivery systems for the treatment of TB. Nanomedicine 2011; 6: 1413–28
   PubMed Web of Science ®Google Scholar
• Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed Nanotechnol Biol Med 2006; 2: 8–21
   PubMed Web of Science ®Google Scholar
• Ranjita S, Loaye A, Khalil M. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci 2011; 14: 100–16
   PubMed Web of Science ®Google Scholar
• Russell D. Who puts the tubercle in tuberculosis?. Nat Rev Microbiol 2007; 5: 39–47
   PubMed Web of Science ®Google Scholar
• Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 2010; 385: 143–9
   PubMed Web of Science ®Google Scholar
• Saraogi GK, Sharma B, Joshi B, Gupta P, Gupta UD, Jain NK, Agrawal GP. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target 2011; 19: 219–27
   PubMed Web of Science ®Google Scholar
• Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomed 2008; 3: 1–19
   PubMed Web of Science ®Google Scholar
• Sosnik A, Carcaboso ÁM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 2010; 62: 547–59
   PubMed Web of Science ®Google Scholar
• Sudhakar Y, Kuotsu K, Bandyopadhyay A. Buccal bioadhesive drug delivery – A promising option for orally less efficient drugs. J Control Release 2006; 114: 15–40
   PubMed Web of Science ®Google Scholar
• Taylor P, Martinez-Pomares L, Stacey M, Lin H-H, Brown G, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23: 901–44
   PubMed Web of Science ®Google Scholar
• Yadav AB, Singh AK, Verma RK, Mohan M, Agrawal AK, Misra A. The devil's advocacy: When and why inhaled therapies for tuberculosis may not work. Tuberculosis 2011; 91: 65–6
   PubMed Web of Science ®Google Scholar
• Yeboah KG, Douza's MJ. Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J Microencapsul 2009; 26: 166–79
   PubMed Web of Science ®Google Scholar
• Zara GP, Bargoni A, Cavalli R, Fundarò A, Vighetto D, Gasco MR. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002; 91: 1324–33
   PubMed Web of Science ®Google Scholar